Your browser doesn't support javascript.
loading
The fibrillinopathies: New insights with focus on the paradigm of opposing phenotypes for both FBN1 and FBN2.
Peeters, Silke; De Kinderen, Pauline; Meester, Josephina A N; Verstraeten, Aline; Loeys, Bart L.
Afiliação
  • Peeters S; Centre of Medical Genetics, University of Antwerp and Antwerp University Hospital, Edegem, Belgium.
  • De Kinderen P; Centre of Medical Genetics, University of Antwerp and Antwerp University Hospital, Edegem, Belgium.
  • Meester JAN; Centre of Medical Genetics, University of Antwerp and Antwerp University Hospital, Edegem, Belgium.
  • Verstraeten A; Centre of Medical Genetics, University of Antwerp and Antwerp University Hospital, Edegem, Belgium.
  • Loeys BL; Centre of Medical Genetics, University of Antwerp and Antwerp University Hospital, Edegem, Belgium.
Hum Mutat ; 43(7): 815-831, 2022 07.
Article em En | MEDLINE | ID: mdl-35419902
Different pathogenic variants in the fibrillin-1 gene (FBN1) cause Marfan syndrome and acromelic dysplasias. Whereas the musculoskeletal features of Marfan syndrome involve tall stature, arachnodactyly, joint hypermobility, and muscle hypoplasia, acromelic dysplasia patients present with short stature, brachydactyly, stiff joints, and hypermuscularity. Similarly, pathogenic variants in the fibrillin-2 gene (FBN2) cause either a Marfanoid congenital contractural arachnodactyly or a FBN2-related acromelic dysplasia that most prominently presents with brachydactyly. The phenotypic and molecular resemblances between both the FBN1 and FBN2-related disorders suggest that reciprocal pathomechanistic lessons can be learned. In this review, we provide an updated overview and comparison of the phenotypic and mutational spectra of both the "tall" and "short" fibrillinopathies. The future parallel functional study of both FBN1/2-related disorders will reveal new insights into how pathogenic fibrillin variants differently affect the fibrillin microfibril network and/or growth factor homeostasis in clinically opposite syndromes. This knowledge may eventually be translated into new therapeutic approaches by targeting or modulating the fibrillin microfibril network and/or the signaling pathways under its control.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fibrilina-1 / Fibrilina-2 / Síndrome de Marfan / Anormalidades Musculoesqueléticas Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fibrilina-1 / Fibrilina-2 / Síndrome de Marfan / Anormalidades Musculoesqueléticas Idioma: En Ano de publicação: 2022 Tipo de documento: Article